Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NewLink Genetics Corporation
Age
3–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligibility Criteria
Age: 3-21 years.
Group 1 or Group 3: histologically proven initial diagnosis of primary malignant brain tumor, with no known curative treatment options.
Group 2: histologically proven initial diagnosis of high-grade glioma (WHO grade III and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor.
Group 3b: Patients with a radiographic diagnosis or histologically proven diagnosis of diffuse intrinsic pontine glioma (DIPG).
MRI confirmation of tumor progression or regrowth.
Patients must be able to swallow whole capsules.
Patients with metastatic disease are eligible for enrollment.
Lansky or Karnofsky performance status score must be \> 50%.
Seizure disorders must be well controlled on antiepileptic medication.
DIPG patients enrolled to Group 3b must not have been previously treated with radiation or any medical therapy.
Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment.
You may not be if
Prior invasive malignancy, other than the primary central nervous system tumor, unless the patient has been disease free and off therapy for that disease for a minimum of 3 years
Patients with baseline QTc interval of more than 470 msec at study entry, and patients with congenital long QTc syndrome.
Active autoimmune disease
Clareo Health | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
